As Aveanna Healthcare Holdings (Nasdaq: AVAH) considers potential acquisitions, hospices are not on the menu due to their high price tags. Hospice multiples skyrocketed during the boom M&A years of 2019 through 2022, reaching as high a 26x, sometimes more. As transactions slowed down between 2023 and 2025, one contributing factor was a disconnect between sellers’ and buyers’ expectations regarding valuations. Now hospice deals are picking up steam. The fourth quarter of 2025 saw the industry’s highest deal volume since 2021, and one reason is that sellers’ and buyers’ expectations are becoming more aligned. However, this trend hasn’t yet gone far enough, according to Aveanna CEO Jeff Shaner.
Read the full article: Aveanna CEO: Hospice Multiples Still Too High //
Source: https://hospicenews.com/2026/02/13/aveanna-ceo-hospice-multiples-still-too-high/